抗生素暴露对晚期肺癌免疫治疗预后的影响_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

谢玉芳 ¹ , 卢亚 ¹ , 袁芳 ¹ ,  胡燕霞 ¹ ,  刘丹 ²

1. ;
2. ;

Corresponding author：

胡燕霞, Email: fb15079239919@163.com; 刘丹, Email: Liudan10965@wchscu.cn

Keywords：

DOI：

10.7507/1671-6205.202405072

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

1.	Siegel RL, Miller KD, Fuchs HE, et al. Cancer Statistics, 2021. CA Cancer J Clin, 2021, 71(1): 7-33.
2.	Reck M, Rodríguez-Abreu D, Robinson AG, et al. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol, 2019, 37(7): 537-546.
3.	Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet, 2017, 389(10066): 255-265.
4.	Lee JB, Kim HR, Ha SJ. Immune checkpoint inhibitors in 10 years: contribution of basic research and clinical application in cancer immunotherapy. Immune Netw, 2022, 22(1): e2.
5.	Tang Q, Chen Y, Li X, et al. The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers. Front Immunol, 2022, 13: 964442.
6.	Hazarika M, Chuk MK, Theoret MR, et al. U. S. FDA approval summary: nivolumab for treatment of unresectable or metastatic melanoma following progression on ipilimumab. Clin Cancer Res, 2017, 23(14): 3484-3488.
7.	Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet, 2016, 387(10027): 1540-1550.
8.	Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med, 2015, 373(2): 123-135.
9.	Bai R, Lv Z, Xu D, et al. Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors. Biomark Res, 2020, 8: 34.
10.	Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol, 2018, 36(17): 1714-1768.
11.	Gaucher L, Adda L, Séjourné A, et al. Associations between dysbiosis-inducing drugs, overall survival and tumor response in patients treated with immune checkpoint inhibitors. Ther Adv Med Oncol, 2021, 13: 17588359211000591.
12.	Ueda K, Yonekura S, Ogasawara N, et al. The impact of antibiotics on prognosis of metastatic renal cell carcinoma in Japanese patients treated with immune checkpoint inhibitors. Anticancer Res, 2019, 39(11): 6265-6271.
13.	Kim H, Lee J E, Hong S H, et al. The effect of antibiotics on the clinical outcomes of patients with solid cancers undergoing immune checkpoint inhibitor treatment: a retrospective study. BMC cancer, 2019, 19: 1-13.
14.	Mohiuddin JJ, Chu B, Facciabene A, et al. Association of antibiotic exposure with survival and toxicity in patients with melanoma receiving immunotherapy. J Natl Cancer Inst, 2021, 113(2): 162-170.
15.	Eng L, Sutradhar R, Niu Y, et al. Impact of antibiotic exposure before immune checkpoint inhibitor treatment on overall survival in older adults with cancer: a population-based study. J Clin Oncol, 2023, 41(17): 3122-3134.
16.	Şen GA, Öztaş NŞ, Değerli E, et al. Effect of antibiotic treatment on immune checkpoint inhibitors efficacy in patients with advanced non-small cell lung cancer. Lung Cancer, 2023, 184: 107347.
17.	Barbosa CMM, Lletí ACC, Sánchez RP, et al. Impact of the use of antibiotics on the clinical response to immune checkpoint inhibitors in patients with non-small cell lung cancer. Rev Esp Quimioter, 2022, 35(6): 551-558.
18.	Lurienne L, Cervesi J, Duhalde L, et al. NSCLC immunotherapy efficacy and antibiotic use: a systematic review and meta-analysis. J Thorac Oncol, 2020, 15(7): 1147-1159.
19.	Abdelhamid A, Tuminello S, Ivic-Pavlicic T, et al. Antibiotic treatment and survival in non-small cell lung cancer patients receiving immunotherapy: a systematic review and meta-analysis. Transl Lung Cancer Res, 2023, 12(12): 2427.
20.	Ochi N, Ichihara E, Takigawa N, et al. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non–small-cell lung cancer differ based on PD-L1 expression. Eur J Cancer, 2021, 149: 73-81.
21.	Geum MJ, Kim C, Kang JE, et al. Broad-spectrum antibiotic regimen affects survival in patients receiving nivolumab for non-small cell lung cancer. Pharmaceuticals, 2021, 14(5): 445.
22.	Zhong J, Xiong D, Liu Y, et al. Association of antibiotic exposure with survival in patients with extensive‐stage small cell lung cancer receiving immune checkpoint inhibitor therapy. Thoracic Cancer, 2024, 15(2): 152-162.
23.	Derosa L, Hellmann MD, Spaziano M, et al. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. Ann Oncol, 2018, 29(6): 1437-1444.
24.	Serpas Higbie V, Rogers J, Hwang H, et al. Antibiotic exposure does not impact immune checkpoint blockade response in MSI-H/dMMR metastatic colorectal cancer: a single-center experience. Oncologist, 2022, 27(11): 952-957.
25.	Cortellini A, Ricciuti B, Facchinetti F, et al. Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy. Ann Oncol, 2021, 32(11): 1391-1399.
26.	Matson V, Fessler J, Bao R, et al. The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients. Science, 2018, 359(6371): 104-108.
27.	Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors. Science, 2018, 359(6371): 91-97.
28.	Gopalakrishnan V, Spencer CN, Nezi L, et al. Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients. Science, 2018, 359(6371): 97-103.
29.	Blaser MJ. Antibiotic use and its consequences for the normal microbiome. Science, 2016, 352(6285): 544-545.
30.	Yin Y, Sichler A, Ecker J, et al. Gut microbiota promote liver regeneration through hepatic membrane phospholipid biosynthesis. J Hepatol, 2023, 78(4): 820-835.
31.	Peng K, Chen K, Teply BA, et al. Impact of proton pump inhibitor use on the effectiveness of immune checkpoint inhibitors in advanced cancer patients. Ann Pharmacother, 2022, 56(4): 377-386.
32.	Chen Q, Zhang Z, Li X, et al. Analysis of prognostic factors affecting immune checkpoint inhibitor therapy in tumor patients exposed to antibiotics. Front Oncol, 2023, 13: 1204248.
33.	Fidelle M, Rauber C, Alves Costa Silva C, et al. A microbiota-modulated checkpoint directs immunosuppressive intestinal T cells into cancers. Science, 2023, 380(6649): eabo2296.
34.	Morita A, Ichihara E, Inoue K, et al. Impacts of probiotics on the efficacies of immune checkpoint inhibitors with or without chemotherapy for patients with advanced non‐small‐cell lung cancer. Int J Cancer, 2024, 154(9): 1607-1615.
35.	Thomas AM, Fidelle M, Routy B, et al. Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy. Nat Rev Clin Oncol, 2023, 20(9): 583-603.
36.	Perrone F, Belluomini L, Mazzotta M, et al. Exploring the role of respiratory microbiome in lung cancer: A systematic review. Crit Rev Oncol Hematol, 2021, 164: 103404.
37.	Li Y, Rao G, Zhu G, et al. Dysbiosis of lower respiratory tract microbiome are associated with proinflammatory states in non‐small cell lung cancer patients. Thorac Cancer, 2024, 15(2): 111-121.
38.	Boesch M, Baty F, Albrich W C, et al. Local tumor microbial signatures and response to checkpoint blockade in non-small cell lung cancer. Oncoimmunology, 2021, 10(1): 1988403.
39.	Jin C, Lagoudas GK, Zhao C, et al. Commensal microbiota promote lung cancer development via γδ T cells. Cell, 2019, 176(5): 998-1013,e16.
40.	Chen P, Hu T, Jiang H, et al. Chronic exposure to ampicillin alters lung microbial composition in laboratory rat. Exp Lung Res, 2023, 49(1): 116-130.
41.	Rofael SAD, Brown J, Lipman MCI, et al. Impact of prophylactic and ‘rescue pack’antibiotics on the airway microbiome in chronic lung disease. BMJ Open Respir Res, 2023, 10(1).
42.	Inam Z, Felton E, Burrell A, et al. Impact of antibiotics on the lung microbiome and lung function in children with cystic fibrosis 1 year after hospitalization for an initial pulmonary exacerbation. Open Forum Infect Dis, 2022, 9(9): ofac466.
43.	Jiang Z, Wei F, Zhang Y, et al. IFI16 directly senses viral RNA and enhances RIG-I transcription and activation to restrict influenza virus infection. Nat Microbiol, 2021, 6(7): 932-945.
44.	Emerson RW, Adams C, Nishino T, et al. Functional neuroimaging of high-risk 6-month-old infants predicts a diagnosis of autism at 24 months of age. Sci Transl Med, 2017, 9(393): eaag2882.
45.	Hao Y, Hao S, Andersen-Nissen E, et al. Integrated analysis of multimodal single-cell data. Cell, 2021, 184(13): 3573-3587,e29.
46.	Sampson TR, Mazmanian SK. Control of brain development, function, and behavior by the microbiome. Cell Host Microbe, 2015, 17(5): 565-576.

1. Siegel RL, Miller KD, Fuchs HE, et al. Cancer Statistics, 2021. CA Cancer J Clin, 2021, 71(1): 7-33.
2. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol, 2019, 37(7): 537-546.
3. Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet, 2017, 389(10066): 255-265.
4. Lee JB, Kim HR, Ha SJ. Immune checkpoint inhibitors in 10 years: contribution of basic research and clinical application in cancer immunotherapy. Immune Netw, 2022, 22(1): e2.
5. Tang Q, Chen Y, Li X, et al. The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers. Front Immunol, 2022, 13: 964442.
6. Hazarika M, Chuk MK, Theoret MR, et al. U. S. FDA approval summary: nivolumab for treatment of unresectable or metastatic melanoma following progression on ipilimumab. Clin Cancer Res, 2017, 23(14): 3484-3488.
7. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet, 2016, 387(10027): 1540-1550.
8. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med, 2015, 373(2): 123-135.
9. Bai R, Lv Z, Xu D, et al. Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors. Biomark Res, 2020, 8: 34.
10. Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol, 2018, 36(17): 1714-1768.
11. Gaucher L, Adda L, Séjourné A, et al. Associations between dysbiosis-inducing drugs, overall survival and tumor response in patients treated with immune checkpoint inhibitors. Ther Adv Med Oncol, 2021, 13: 17588359211000591.
12. Ueda K, Yonekura S, Ogasawara N, et al. The impact of antibiotics on prognosis of metastatic renal cell carcinoma in Japanese patients treated with immune checkpoint inhibitors. Anticancer Res, 2019, 39(11): 6265-6271.
13. Kim H, Lee J E, Hong S H, et al. The effect of antibiotics on the clinical outcomes of patients with solid cancers undergoing immune checkpoint inhibitor treatment: a retrospective study. BMC cancer, 2019, 19: 1-13.
14. Mohiuddin JJ, Chu B, Facciabene A, et al. Association of antibiotic exposure with survival and toxicity in patients with melanoma receiving immunotherapy. J Natl Cancer Inst, 2021, 113(2): 162-170.
15. Eng L, Sutradhar R, Niu Y, et al. Impact of antibiotic exposure before immune checkpoint inhibitor treatment on overall survival in older adults with cancer: a population-based study. J Clin Oncol, 2023, 41(17): 3122-3134.
16. Şen GA, Öztaş NŞ, Değerli E, et al. Effect of antibiotic treatment on immune checkpoint inhibitors efficacy in patients with advanced non-small cell lung cancer. Lung Cancer, 2023, 184: 107347.
17. Barbosa CMM, Lletí ACC, Sánchez RP, et al. Impact of the use of antibiotics on the clinical response to immune checkpoint inhibitors in patients with non-small cell lung cancer. Rev Esp Quimioter, 2022, 35(6): 551-558.
18. Lurienne L, Cervesi J, Duhalde L, et al. NSCLC immunotherapy efficacy and antibiotic use: a systematic review and meta-analysis. J Thorac Oncol, 2020, 15(7): 1147-1159.
19. Abdelhamid A, Tuminello S, Ivic-Pavlicic T, et al. Antibiotic treatment and survival in non-small cell lung cancer patients receiving immunotherapy: a systematic review and meta-analysis. Transl Lung Cancer Res, 2023, 12(12): 2427.
20. Ochi N, Ichihara E, Takigawa N, et al. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non–small-cell lung cancer differ based on PD-L1 expression. Eur J Cancer, 2021, 149: 73-81.
21. Geum MJ, Kim C, Kang JE, et al. Broad-spectrum antibiotic regimen affects survival in patients receiving nivolumab for non-small cell lung cancer. Pharmaceuticals, 2021, 14(5): 445.
22. Zhong J, Xiong D, Liu Y, et al. Association of antibiotic exposure with survival in patients with extensive‐stage small cell lung cancer receiving immune checkpoint inhibitor therapy. Thoracic Cancer, 2024, 15(2): 152-162.
23. Derosa L, Hellmann MD, Spaziano M, et al. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. Ann Oncol, 2018, 29(6): 1437-1444.
24. Serpas Higbie V, Rogers J, Hwang H, et al. Antibiotic exposure does not impact immune checkpoint blockade response in MSI-H/dMMR metastatic colorectal cancer: a single-center experience. Oncologist, 2022, 27(11): 952-957.
25. Cortellini A, Ricciuti B, Facchinetti F, et al. Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy. Ann Oncol, 2021, 32(11): 1391-1399.
26. Matson V, Fessler J, Bao R, et al. The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients. Science, 2018, 359(6371): 104-108.
27. Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors. Science, 2018, 359(6371): 91-97.
28. Gopalakrishnan V, Spencer CN, Nezi L, et al. Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients. Science, 2018, 359(6371): 97-103.
29. Blaser MJ. Antibiotic use and its consequences for the normal microbiome. Science, 2016, 352(6285): 544-545.
30. Yin Y, Sichler A, Ecker J, et al. Gut microbiota promote liver regeneration through hepatic membrane phospholipid biosynthesis. J Hepatol, 2023, 78(4): 820-835.
31. Peng K, Chen K, Teply BA, et al. Impact of proton pump inhibitor use on the effectiveness of immune checkpoint inhibitors in advanced cancer patients. Ann Pharmacother, 2022, 56(4): 377-386.
32. Chen Q, Zhang Z, Li X, et al. Analysis of prognostic factors affecting immune checkpoint inhibitor therapy in tumor patients exposed to antibiotics. Front Oncol, 2023, 13: 1204248.
33. Fidelle M, Rauber C, Alves Costa Silva C, et al. A microbiota-modulated checkpoint directs immunosuppressive intestinal T cells into cancers. Science, 2023, 380(6649): eabo2296.
34. Morita A, Ichihara E, Inoue K, et al. Impacts of probiotics on the efficacies of immune checkpoint inhibitors with or without chemotherapy for patients with advanced non‐small‐cell lung cancer. Int J Cancer, 2024, 154(9): 1607-1615.
35. Thomas AM, Fidelle M, Routy B, et al. Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy. Nat Rev Clin Oncol, 2023, 20(9): 583-603.
36. Perrone F, Belluomini L, Mazzotta M, et al. Exploring the role of respiratory microbiome in lung cancer: A systematic review. Crit Rev Oncol Hematol, 2021, 164: 103404.
37. Li Y, Rao G, Zhu G, et al. Dysbiosis of lower respiratory tract microbiome are associated with proinflammatory states in non‐small cell lung cancer patients. Thorac Cancer, 2024, 15(2): 111-121.
38. Boesch M, Baty F, Albrich W C, et al. Local tumor microbial signatures and response to checkpoint blockade in non-small cell lung cancer. Oncoimmunology, 2021, 10(1): 1988403.
39. Jin C, Lagoudas GK, Zhao C, et al. Commensal microbiota promote lung cancer development via γδ T cells. Cell, 2019, 176(5): 998-1013,e16.
40. Chen P, Hu T, Jiang H, et al. Chronic exposure to ampicillin alters lung microbial composition in laboratory rat. Exp Lung Res, 2023, 49(1): 116-130.
41. Rofael SAD, Brown J, Lipman MCI, et al. Impact of prophylactic and ‘rescue pack’antibiotics on the airway microbiome in chronic lung disease. BMJ Open Respir Res, 2023, 10(1).
42. Inam Z, Felton E, Burrell A, et al. Impact of antibiotics on the lung microbiome and lung function in children with cystic fibrosis 1 year after hospitalization for an initial pulmonary exacerbation. Open Forum Infect Dis, 2022, 9(9): ofac466.
43. Jiang Z, Wei F, Zhang Y, et al. IFI16 directly senses viral RNA and enhances RIG-I transcription and activation to restrict influenza virus infection. Nat Microbiol, 2021, 6(7): 932-945.
44. Emerson RW, Adams C, Nishino T, et al. Functional neuroimaging of high-risk 6-month-old infants predicts a diagnosis of autism at 24 months of age. Sci Transl Med, 2017, 9(393): eaag2882.
45. Hao Y, Hao S, Andersen-Nissen E, et al. Integrated analysis of multimodal single-cell data. Cell, 2021, 184(13): 3573-3587,e29.
46. Sampson TR, Mazmanian SK. Control of brain development, function, and behavior by the microbiome. Cell Host Microbe, 2015, 17(5): 565-576.

Chinese Journal of Respiratory and Critical Care Medicine

Latest Articles抗生素暴露对晚期肺癌免疫治疗预后的影响

Abstract Full text Figures/Tables Video References Cited by

Format

Content